Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quavonlimab - Merck Sharp & Dohme

Next Previous
Drug Profile

Quavonlimab - Merck Sharp & Dohme

Alternative Names: AK-107; MK-1308

Latest Information Update: 24 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer Merck Sharp & Dohme
  • Class Antineoplastics; Biological factors; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Malignant melanoma; Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 08 Apr 2024 Merck Sharp & Dohme completes the Phase-I/II clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease) in USA, Australia, Canada, Chile, France, Greece, Israel, Italy, Japan, New Zealand, Poland, South Korea, Spain, Sweden, South Africa (IV) (NCT03179436)
  • 13 May 2021 Phase-II clinical trials in Liver cancer (Combination therapy) (IV) (Merck pipeline, May 2021)
  • 16 Feb 2021 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in France (IV) (EudraCT2020-003742-36)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top